EP12.02. PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Xinyu Liu
Meta Tag
Speaker Xinyu Liu
Topic Metastatic NSCLC: Targeted Therapy - FUSIONS
programmed cell death-ligand 1
PD-L1 expression
ALK-rearranged lung cancer
first-line therapy
baseline PD-L1 expression levels
objective response rate
progression-free survival
ALK tyrosine kinase inhibitors
Powered By